Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.

AIMS

The objective was to assess weight reduction at Weeks 24 and 72 in participants treated with tirzepatide based on weight reduction response after 12 weeks of treatment in the SURMOUNT-1 trial.

MATERIALS AND METHODS

This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and had weight measurements at Weeks 0, 12, 24 and 72. Participants were categorized based on the 12-week response to tirzepatide: late responders (<5% weight reduction at Week 12) or early responders (≥5% weight reduction at Week 12).

RESULTS

A total of 1545 participants were included in the analyses, with 278 (18%) categorized as late responders and 1267 (82%) categorized as early responders. At baseline, late responders compared to early responders were more likely to be male (45% vs. 30%) and had higher body weight (110.2 vs. 103.6 kg), body mass index (BMI) (39.1 vs. 37.7 kg/m) and waist circumference (117.5 vs. 113.4 cm). At the end of dose titration, Week 24, 194 (70%) late responders achieved ≥5% body weight reduction. At Week 72, 250 (90%) late responders achieved ≥5% body weight reduction. The mean time to reach 5% weight reduction for late responders was 24.8 ± 12.7 weeks. Higher doses of tirzepatide were associated with higher proportions of participants achieving various weight reduction thresholds at Weeks 24 and 72.

CONCLUSIONS

Among late responders to tirzepatide, the vast majority (90%) achieved 5% or more weight reduction at Week 72. This finding suggests that extending treatment well beyond 12 weeks may allow additional patients to achieve clinically meaningful weight reduction.

TRIAL REGISTRATION

ClinicalTrials.gov, identifier: NCT04184622, available at http://www.

CLINICALTRIALS

gov/.